Frazier Life Sciences Management Portfolio holdings
Frazier Life Sciences is a biotech investment firm that backs companies developing new drugs, from their formation through to public markets. It started operations in 2022 and is owned mainly by Jamie Topper and Patrick Heron. Its Public Fund invests mainly in listed drug and biotech companies, with up to a fifth of its portfolio available for financings of private ones, while the firm's other funds mostly back private companies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HilleVax
HLVX
|
+$110M |
| 2 |
Krystal Biotech
KRYS
|
+$14.3M |
| 3 |
KDNY
Chinook Therapeutics
KDNY
|
+$13.9M |
| 4 |
Tarsus Pharmaceuticals
TARS
|
+$5.56M |
| 5 |
Cerevel Therapeutics Holdings
CERE
|
+$4.16M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SRRA
Sierra Oncology
SRRA
|
+$77.2M |
| 2 |
ISEE
IVERIC bio
ISEE
|
+$28.3M |
| 3 |
Bicycle Therapeutics
BCYC
|
+$26.5M |
| 4 |
Vaxcyte
PCVX
|
+$12.1M |
| 5 |
Alpine Immune Sciences Inc
ALPN
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.6% |
| 2 | Miscellaneous | 1.4% |
Similar funds
Frazier Life Sciences Management's Q2 2022 Portfolio in Review
As of Q2 2022, Frazier Life Sciences Management held 44 positions worth $1.06B, down 9.7% from $1.17B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Frazier Life Sciences Management's Q2 2022 filing shows 2 new, 8 increased, 8 reduced and 3 closed positions. Its largest new stake was HilleVax: 9,285,682 shares worth $101M. The largest sale was Sierra Oncology, an estimated $77.2M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
- Frazier Life Sciences Management's largest Q2 2022 buy was HilleVax: 9,285,682 shares worth $101M.
- Frazier Life Sciences Management added most to Krystal Biotech in Q2 2022, an estimated $14.3M increase.
- Frazier Life Sciences Management's biggest Q2 2022 reduction was Sierra Oncology, cutting an estimated $77.2M.
- Frazier Life Sciences Management fully exited Bicycle Therapeutics in Q2 2022, selling an estimated $26.5M.
- Frazier Life Sciences Management's ten largest holdings make up 68% of its $1.06B portfolio in Q2 2022.
- Frazier Life Sciences Management opened 2 new positions and closed 3 in Q2 2022.
- Frazier Life Sciences Management's portfolio value fell 9.7% quarter-over-quarter to $1.06B.
Based on Frazier Life Sciences Management's 13F filing for Q2 2022, filed 10 Aug 2022.